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not differ for their scores on CPD or nicotine dependence (Psy-D/Phys-Smoking cessation improves clinical
outcome in severe mental disorders and is
modulated by genetic variability at CHRNA5
geneSmoking has been traditionally tolerated for patients withmental disor-
ders due to its hypothesized self-medication function (Schroeder and
Morris, 2010). Although tobacco use has been associated with greater
symptom severity and other health-threatening conditions, persons di-
agnosed with a mental disorder are 2–4 times more prone to smoking
than the general population (Aubin et al., 2012). Both self-medication
and shared vulnerability hypotheses have been considered to under-
stand increasing use of tobacco in mental disorders (Sagud et al.,
2018). Genetic studies report high heritability rates of nicotine depen-
dence (~60%) (Berrettini and Doyle, 2012). The nicotinic receptor
(nAChR), and specifically the nAChR subunit genes CHRNA5/A3/B4/A7
have been associatedwith nicotine addiction, smoking cessation and se-
vere mental disorders (Han et al., 2019; Jackson et al., 2013).
In order to examine whether smoking cessation i) affected the ill-
ness severity course and ii) was modulated by CHRNA5/A7 variability,
we analysed a sample of 60 patients with schizophrenia (n=48) or bi-
polar disorder (n = 12) under a smoking cessation treatment for
36weeks.We assessed the self-reported cigarettes per day (CPD), nico-
tine psychological (Psy-D) and physical (Phys-D) dependence and ill-
ness severity. Cessation treatment consisted of the use of transdermal
nicotine patches (TNP) or varenicline. Atweek 36, patientswere consid-
ered abstinent (ABS) if CPD= 0 the last 7 days and breath carbonmon-
oxide was b9 ppm. SNPs at CHRNA5 (rs680244, rs16969968) and
CHRNA7 (rs6494223) were genotyped using TaqMan exonuclease
assay (Applied Biosystems) (all SNPs were in Hardy-Weinberg equilib-
rium) (See Supplementary Methodology). All statistical approaches are
detailed in Supplementary Material.
Clinical variables were measured at baseline and weeks 12, 24 and
36 after smoking cessation treatment initiation (Table 1). Genotype dis-
tributions of SNPs are shown in Supplementary Table 1. The Clinical Re-
search Ethics Committee of Hospital Universitario Central de Asturias in
Oviedo approved the study protocol (Ref. 64/2010). Written informed
consent was obtained from all subjects before enrolment.
At baseline, CPD was positively correlated with basal nicotine Psy-D
(r = 0.317; p = 0.015), Phys-D (r = 0.307; p = 0.017), illness severity
(r = 0.313; p = 0.015) and associated with gender [males (mean =
31.66 ± 12.53) vs females (mean = 24.26 ± 7.64); t53.44 = 2.815; p =
0.007]. Moreover, a trend of association was found between baseline
CPD and rs680244 genotype distribution (p = 0.076) (Supplementary
Table 2) with T-carriers consuming more CPD than CC individuals
(31.65±12.64 vs 24.65±7.79, respectively; t55.27=−2.639; p=0.011).
At week 36, 24 (40%) patients were classified as ABS and 36 (60%) as
non-abstinent (nonABS). Both groups were equivalent in terms of gen-
der (χ21=0.428; p=0.572), age (t41=1.055; p=0.289) and diagnosis
(χ21= 0.147; p=0.193).When comparing, ABS and nonABS groups didhttps://doi.org/10.1016/j.schres.2020.05.024
0920-9964/© 2020 Elsevier B.V. All rights reserved.
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lower scores in all three measures (p b 0.001 for all measurements)
(Table 1). Interestingly, although ABS and nonABS patients reported
similar illness severity scores at baseline, ABS showed a significant de-
crease of their illness severity at week 12 (p = 0.019), 24 (p = 0.012)
and 36 (p = 0.021) (Table 1).
Additionally, CHRNA5-rs680244-CC had 4 times more risk of being
nonABS at week 36 than T-carriers (OR = 4; 95%CI [1.13, 14.08]; χ21=
5.00; p = 0.03). No statistical differences were found for the other
SNPs (Supplementary Table 2).
Our results showed higher tobacco consumption in males and – as
previously reported but still a subject of controversy – no gender differ-
ences in cessation success (Filia et al., 2014). In line with previous liter-
ature, we found positive correlations between CPD, nicotine
dependence and illness severity at baseline (Dodd et al., 2010; Donny
et al., 2008).
Smoking cessation groups did not differ for baseline CPD, Psy-D,
Phys-D or illness severity, suggesting that cessation treatment success
was independent from these variables. ABS patients reported lower ill-
ness severity since the first assessment after treatment initiation. Like-
wise, previous studies show that smoker patients with schizophrenia
or bipolar disorder report worse global psychopathological status
(Dodd et al., 2010; Krishnadas et al., 2012).
The relationship between severe mental disorders and smoking is
complex and so far remains inconclusive. Nonetheless, it is widely ac-
cepted that dysfunction in central nAChRs represents a common sub-
strate for schizophrenia and comorbid nicotine dependence. Our work
reflected the effect of CHRNA5 on initial tobacco use and smoking cessa-
tion success. Intriguingly, the rs680244-T allele was associated with
both higher baseline CPD and greater treatment success. These results
fit with the hypothesis of conceptualizing genes as “plasticity genes” in-
stead of “vulnerability genes”, leading susceptible individuals to both
adverse and positive environmental influences (Belsky et al., 2009). Pre-
vious results showed that replacement therapy response (Sarginson et
al., 2011) andnicotinedependence (Greenbaumet al., 2006)were influ-
enced by rs680244. Despite intronic, rs680244 acts as an expression
quantitative trait loci (eQTL) with the T allele increasing CHRNA5 ex-
pression in multiple brain regions.
No significant results were found for CHRNA5-rs16969968, although
it is considered a well-established risk factor for nicotine dependence
(Hong et al., 2011) or CHRNA7-rs6494223 that – as far as we know –
no previous studies have explored its association with illness severity
or smoking cessation.
The results of this work should be interpreted in the context of sev-
eral limitations: i) the open-labelled and non-randomized nature of the
study, ii) the lack of an untreated control group may impair the robust-
ness of our results, iii) our sample could be considered small for a ge-
netic approach although a 36-week longitudinal design with extensive
and exhaustive psychopathological assessments was considered and a
very low dropout rate was detected, iv) multiple testing corrections
were not applied since we considered they were likely to be excessiveoking cessation improves clinical outcome in severe mental disorders
search, https://doi.org/10.1016/j.schres.2020.05.024
Table 1
Assessment of CPD, Psy-D, Phys-D and illness severity along the follow-up in ABS and nonABS patients (defined at week 36) after initiation of the smoking cessation program.
Assessment Week All patients mean(SD) ABS patients mean(SD) nonABS patients mean(SD) t df p-Value
CPD 0 29.32(11.67) 29.00(12.22) 29.53(11.45) −0.170 58.00 0.865
12 5.98(8.90) 0.17(0.82) 9.86(9.72) −5.951 35.74 b0.001
24 9.23(10.64) 0.00(0.00) 15.39(9.66) 35.000 35.00 b0.001
36 8.75(9.54) 0.00(0.00) 14.58(8.12) 35.000 35.00 b0.001
Psy-D 0a 17.41(6.74)a 15.87(4.78) 18.45(7.67) −1.427 55.89 0.123
12 7.35(7.84) 3.13(3.44) 10.17(8.68) −4.380 49.23 b0.001
24 8.26(8.58) 2.29(2.49) 12.28(8.89) −6.373 42.84 b0.001
36 8.98(8.84) 2.83(3.38) 13.08(9.00) −6.204 48.11 b0.001
Phys-D 0 6.18(2.58) 5.92(2.98) 6.36(3.31) 0.650 58.00 0.581
12 2.18(2.97) 0.21(0.83) 3.50(3.16) −5.952 41.99 b0.001
24 2.63(3.16) 0.04(0.20) 4.36(3.03) −8.538 35.48 b0.001
36 3.02(3.08) 0.25(0.85) 4.86(2.59) −9.889 45.29 b0.001
Illness severity 0a 3.50(0.99)a 3.26(1.09) 3.66(0.91) −1.499 56.00 0.139
12a 3.34(1.07)a 2.96(1.04) 3.62(1.02) −2.410 56.00 0.019
24 3.37(1.15) 2.92(1.18) 3.67(1.04) −2.549 58.00 0.012
36 3.40(1.11) 3.00(1.06) 3.67(1.07) −2.372 58.00 0.021
ABS: abstinent; nonABS: non-abstinent; CPD: cigarettes per day; Psy-D: nicotine psychological dependence; Phys-D: nicotine physical dependence. Significant results aremarked in bold.
a n = 58.
2 Letter to the Editorin this context in which the selection of the variables of interest and the
analyses were performed under a directional hypothesis based on pre-
vious findings, v) only three genetic variants were analysed to explain
complex and multifactorial phenotypes such as tobacco use and
smoking cessation success.
Current trends aim to challenge the disregard of health-threatening
effects of tobacco in patientswithmental disorders and encourage clini-
cians to implement the available tools for smoking cessation in mental
healthcare facilities (García-Portilla and Bobes, 2016). Further genetic
studies could better explain nicotine addiction and ultimately provide
tools for personalized therapies.
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